Skip to main navigation Skip to main content
The University of Southampton
Southampton Clinical Trials Unit

ARGO

Title

A phase II Study of Atezolizumab with Rituximab, Gemcitabine and Oxaliplatin in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma who are not candidates for High Dose Therapy

Description

ARGO is a phase II trial evaluating the addition of Atezolizumab to current therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) that are not candidates for high-dose therapy.

Objectives

Primary objective:

Secondary objectives:

Tertiary objectives:

Trial Design

This was a multicentre, randomised phase IIa trial in participants with relapsed or refractory DLBCL.

This study had two treatment arms.

All patients received one cycle of R-GemOx. Three quarters of patients (Arm B) went on to have a further 5 cycles (every 14 days) of R-GemOx with Atezolizumab, with one quarter of patients (Arm A) continuing with 5 cycles of R-GemOx.

The patients in Arm B continued to have Atezolizumab every 21 days for 8 cycles whilst Arm A patients entered an observational phase during this time.

Follow up began at 12 months from initial treatment until month 36.

Trial Status

Completed

Population

Patients aged ≥16 years with relapsed or refractory Diffuse Large B-Cell Lymphoma that are not candidates for high-dose therapy.

Contact Details

All trial enquiries should be sent to [email protected]

Publications

Poster presentation at the International Conference on Malignant Lymphoma, June 2021

Funding

CRUK logo

This trial was endorsed by Cancer Research UK (award reference no. C30423/A23607)

Find our more about ARGO on the Cancer Research UK website .

Privacy Settings
Powered by Fruition